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Monoclonal antibodies (mAbs) are currently the most important class of recombinant protein therapeutics in the 
biotechnological and biopharmaceutical industry with more than 250 mAbs currently undergoing clinical trials. 
High titer producing cultures and complex mixtures containing high cell densities, together with an increasing 
growing demand for highly pure mAbs is making recovery and purification processes hot targets for 
improvement and opens important technological challenges in mAbs manufacturing platforms. 
 
This work explores the use of an affinity dual ligand based on a choline binding polypeptide tag (LYTAG) fused 
with the synthetic antibody Z domain (LYTAG-Z) as a tool to integrate and optimized the downstream 
processing of mAbs.  Upon addition of this ligand to an animal cell culture broth, antibody-LYTAG-Z complexes 
are formed which can be easily captured and separated from host cell impurities by affinity partitioning in 
aqueous two-phase systems (ATPS) composed of polyethylene glycol –PEG, as PEG molecules have the ability 
to binding to the choline binding sites of LYTAG. Integration of clarification and primary mAbs recovery was 
successfully accomplished using a system composed of 6% PEG 3350 Da and 7% dextran 500,000 Da in which 
an extraction yield of 89% and a clarification higher than 95% were achieved. IgG-rich phases were further 
processed by chromatography, using three different strong anion exchange matrices charged with quaternary 
methyl amines (a choline analogue) – CIMmultus QA, HiTrap Q FF and gPore NW Q. A two-elution method was 
developed for the separation of the antibody-LYTAG-Z complexe, allowing simultaneous purification of the 
antibody and recovery of the ligand.  
 
The process was successfully scale-up 10000 times allowing a global antibody recovery of 70% with a purity of 
89% and enabling 100% cell removal. 
 
